Substituted Dihydropyrrolopyrazole Compound

CLAIMS 1. A compound represented by formula (I) or a pharmacologically acceptable salt thereof: [Chemical Formula 1 ] N-^-V P V-NH L3-0 wherein L1 is an optionally substituted linear or branched C,.6 alkylene group, an optionally substituted linear or branched C2-6 alkenylene group, an optionally substituted linear or branched C2-6 alkynylene group, an optionally substituted C3.6 cycloalkylene group, or an optionally substituted C3.6 cycloalkenylene group, L is a single bond, an oxygen atom, an optionally substituted nitrogen atom, an optionally substituted linear or branched C,.6 alkylene group, an optionally substituted linear or branched C2-6 alkenylene group, an optionally substituted linear or branched C2.6 alkynylene group, an optionally substituted C3.6 cycloalkylene group, or an optionally substituted C3.6 cycloalkenylene group, L" is a single bond, an optionally substituted linear or branched C|_6 alkylene group, an optionally substituted linear or branched C2-6 alkenylene group, an optionally substituted linear or branched Cq.(, alkynylene group, an optionally substituted C3.r, cycloalkylene group, or an optionally substituted C3.6 cycloalkenylene group,

R1, R% and R3 are each independently an optionally substituted linear or branched CM alkyl group, an optionally substituted linear or branched C2-4 alkenyl group, an optionally substituted linear or branched C2-4 alkynyl group, an optionally substituted C6-io aryl group, or an optionally substituted heterocyclic group, R is a hydrogen atom, an optionally substituted linear or branched C|_6 alkyl group, an optionally substituted linear or branched C2-6 alkenyl group, an optionally substituted linear or branched C2.6 alkynyl group, an optionally substituted C3.6 cycloalkyl group, an optionally substituted C3.6 cycloalkenyl group, an optionally substituted C6-m aryl group, or an optionally substituted heterocyclic group, and R is a hydrogen atom, an optionally substituted linear or branched C1.16 alkyl group, an optionally substituted linear or branched C2.!6 alkenyl group, an optionally substituted linear or branched C2.i6 alkynyl group, an optionally substituted C3.6 cycloalkyl group, an optionally substituted C3.6 cycloalkenyl group, an optionally substituted C6.10 aryl group, or an optionally substituted heterocyclic group. 2. The compound or a pharmacologically acceptable salt thereof according to claim 1, wherein L1 is an optionally substituted linear or branched C^ alkylene group or an optionally substituted C3.6 cycloalkylene group. 3. A compound represented by formula (II) or a pharmacologically acceptable salt thereof:

Chemical Formula 2

Y-NH L3-0 >CR' ^ (II) SI wherein L2 is a single bond, an oxygen atom, an optionally substituted nitrogen atom, an optionally substituted linear or branched Ci_6 alkylene group, an optionally substituted linear or branched C2.6 alkenylene group, an optionally substituted linear or branched C2-6 alkynylene group, an optionally substituted C^.b cycloalkylene group, or an optionally substituted C3.6 cycloalkenylene group, L3 is a single bond, an optionally substituted linear or branched C1.6 alkylene group, an optionally substituted linear or branched C2.6 alkenylene group, an optionally substituted linear or branched C2„6 alkynylene group, an optionally substituted C3_6 cycloalkylene group, or an optionally substituted C3.6 cycloalkenylene group, R', R , and RJ are each independently an optionally substituted linear or branched C[_4 alkyl group, an optionally substituted linear or branched C2.4 alkenyl group, an optionally substituted linear or branched C2_4 alkynyl group, an optionally substituted Q,.io aryl group, or an optionally substituted heterocyclic group, R4 is a hydrogen atom, an optionally substituted linear or branched Cj_6 alkyl group, an optionally substituted linear or branched C2_6 alkenyl group, an optionally substituted linear or branched C2_6 alkynyl group, an optionally substituted C3.6 cycloalkyl group, an

optionally substituted C3_6 cycloalkenyl group, an optionally substituted C6.10 aryl group, or an optionally substituted heterocyclic group, and R5 is a hydrogen atom, an optionally substituted linear or branched CM6 alkyl group, an optionally substituted linear or branched C2.l6 alkenyl group, an optionally substituted linear or branched C2-16 alkynyl group, an optionally substituted C3.6 cycloalkyl group, an optionally substituted C3_6 cycloalkenyl group, an optionally substituted C6-10 aryl group, or an optionally substituted heterocyclic group. 4. The compound or a pharmacologically acceptable salt thereof according to claim 3, wherein R1, R2, and R3 each independently represent an optionally substituted linear or branched C1.4 alkyl group. 5. A compound represented by formula (III) or a pharmacologically acceptable salt thereof:

Chemical Formula 3

H^r^\ P °V-NH L3-0 f^V R5 ( I I 1 ) R3 R wherein L2 is a single bond, an oxygen atom, an optionally substituted nitrogen atom, an optionally substituted linear or branched Cu, alkylene group, an optionally substituted linear or branched C2-6 alkenylene group, an optionally substituted linear or branched C2-6 alkynylene group, an optionally substituted C3.6 cycloalkylene group, or an optionally substituted C3.6 cycloalkenylene group,

L3 is a single bond, an optionally substituted linear or branched Cj_6 alkylene group, an optionally substituted linear or branched C2-6 alkenylene group, an optionally substituted linear or branched C2.6 alkynylene group, an optionally substituted C3.<-, cycloalkylene group, or an optionally substituted C3.6 cycloalkenylene group, R', Rz, and RJ are each independently an optionally substituted linear or branched Ci„4 alkyi group, an optionally substituted linear or branched C2.4 alkenyl group, an optionally substituted linear or branched C2-4 alkynyl group, an optionally substituted Q.io aryl group, or an optionally substituted heterocyclic group, R is a hydrogen atom, an optionally substituted linear or branched C,.6 alkyl group, an optionally substituted linear or branched C2-6 alkenyl group, an optionally substituted linear or branched C2-e alkynyl group, an optionally substituted C3.6 cycloalkyl group, an optionally substituted C3.6 cycloalkenyl group, an optionally substituted Ce-jo aryl group, or an optionally substituted heterocyclic group, and R5 is a hydrogen atom, an optionally substituted linear or branched CM6 alkyl group, an optionally substituted linear or branched C2-16 alkenyl group, an optionally substituted linear or branched C2.i6 alkynyl group, an optionally substituted C3.6 cycloalkyl group, an optionally substituted C3.6 cycloalkenyl group, an optionally substituted C6-10 aryl group, or an optionally substituted heterocyclic group. 6. The compound or a pharmacologically acceptable salt thereof according to claim 5, wherein R1, R2, and R3 are each independently an optionally substituted linear or branched C1.4 alkyl group. 7. A compound represented by formula (IV) or a

pharmacologically acceptable salt thereof: [Chemical Formula 4] M' N-f R" V-NH L3-0 wherein L* is a single bond, an oxygen atom, an optionally substituted nitrogen atom, an optionally substituted linear or branched C|.f, alkylene group, an optionally substituted linear or branched C2.f, alkenylene group, an optionally substituted linear or branched C2-6 alkynylene group, an optionally substituted C3.6 cycloalkylene group, or an optionally substituted C3.6 cycloalkenylene group, L3 is a single bond, an optionally substituted linear or branched C)_6 alkylene group, an optionally substituted linear or branched C2-6 alkenylene group, an optionally substituted linear or branched C2-6 alkynylene group, an optionally substituted C3.6 cycloalkylene group, or an optionally substituted C3.6 cycloalkenylene group, R', R2, and R3 are each independently an optionally substituted linear or branched Ci_4 alkyl group, an optionally substituted linear or branched C2_4 alkenyl group, an optionally substituted linear or branched C2-4 alkynyl group, an optionally substituted Cf,_ i () aryl group, or an optionally substituted heterocyclic group, R is a hydrogen atom, an optionally substituted linear or branched Cj.6 alkyl group, an optionally substituted linear or branched

C2.6 alkenyl group, an optionally substituted linear or branched C2_6 alkynyl group, an optionally substituted C3.6 cycloalkyl group, an optionally substituted C3.<5 cycloalkenyl group, an optionally substituted C6.io aryl group, or an optionally substituted heterocyclic group, and R5 is a hydrogen atom, an optionally substituted linear or branched CM6 alky) group, an optionally substituted linear or branched C2-16 alkenyl group, an optionally substituted linear or branched C2-16 alkynyl group, an optionally substituted C3.6 cycloalkyl group, an optionally substituted C3.6 cycloalkenyl group, an optionally substituted C6-10 aryl group, or an optionally substituted heterocyclic group, 8. The compound or a pharmacologically acceptable salt thereof according to claim 7, wherein R1, R2, and R3 are each independently an optionally substituted linear or branched ClA alkyl group. 9. A compound represented by formula (V) or (VI) or a pharmacologically acceptable salt thereof:

Chemical Formula 5

N->-~A P N-~~r^\ P N I) N-f R" Nx I N^f R" V"^7 I 7—( \^^J ,2 / O/ \ 0/ ^ , -y-NH L3-0 y-NH L3-0 I \ / \ K R3 R2 (V) R3 R2 (v , ) wherein L is an optionally substituted linear or branched Cu, alkylene group, an optionally substituted linear or branched C2-6 alkenylene group, an optionally substituted linear or branched C2-6 alkynylene group, an optionally substituted Cv6 cycloalkylene group, or an

optionally substituted C3.6 cycloalkenylene group, L2 is a single bond, an oxygen atom, an optionally substituted nitrogen atom, an optionally substituted linear or branched Ci_6 alkylene group, an optionally substituted linear or branched C2-6 alkenylene group, an optionally substituted linear or branched C2.(, alkynylene group, an optionally substituted C3.6 cycloalkylene group, or an optionally substituted C3.6 cycloalkenylene group, L3 is a single bond, an optionally substituted linear or branched Ci-6 alkylene group, an optionally substituted linear or branched C2,6 alkenylene group, an optionally substituted linear or branched C2-6 alkynylene group, an optionally substituted C3.6 cycloalkylene group, or an optionally substituted C3.6 cycloalkenylene group, R1, R2, and R3 are each independently an optionally substituted linear or branched C|.4 alkyl group, an optionally substituted linear or branched C2-4 alkenyl group, an optionally substituted linear or branched C2-4 alkynyl group, an optionally substituted C6-10 aiyl group, or an optionally substituted heterocyclic group, R is a hydrogen atom, an optionally substituted linear or branched Ci.6 alkyl group, an optionally substituted linear or branched C2_6 alkenyl group, an optionally substituted linear or branched C2-6 alkynyl group, an optionally substituted C3.6 cycloalkyl group, an optionally substituted C3.6 cycloalkenyl group, an optionally substituted Cfi-io aryl group, or an optionally substituted heterocyclic group, R6 is a hydrogen atom, an optionally substituted linear or branched Ci_i6 alkyl group, an optionally substituted linear or branched C2.i6 alkenyl group, an optionally substituted linear or branched C2-16

alkynyl group, an optionally substituted C3_6 cycloalkyl group, an optionally substituted C3.6 cycloalkenyl group, an optionally substituted linear or branched C{.6 alkoxy group, an optionally substituted C6.io aryl group, or an optionally substituted heterocyclic group, R7 is an optionally substituted linear or branched C].l6 alkyl group, an optionally substituted linear or branched C2-16 alkenyl group, an optionally substituted linear or branched C2-16 alkynyl group, an optionally substituted C3.6 cycloalkyl group, an optionally substituted C3.<5 cycloalkenyl group, an optionally substituted C6-io aryl group, or an optionally substituted heterocyclic group, and R8 and R9 are each independently a hydrogen atom or a CM alkyl group. 10. The compound or a pharmacologically acceptable salt thereof according to claim 9, wherein L1 is an optionally substituted linear or branched C|.6 alkylene group or an optionally substituted C3.6 1 0 1 cycloalkylene group, and R , R , and R are each independently an optionally substituted linear or branched CM alkyl group. 11. A compound selected from a compound group consisting of (S)-N-(2-hydroxy-l-phenylethyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cycl obutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carbox amide, (S)-N-(2-hydroxy-l-phenylethyl)-6,6-dimethyl-3~[l-(trimethylsilyl)cycl opropanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carbo xamide, (S)-N-(2-hydroxy-l-phenylethyl)-6,6-dimethyl-3-[2-methyl-2-(trimethy lsilyl)propaneamido]-4,6-dihydropyn-olo[3,4-c]pyrazole-5(lH)-carboxa

mide, (S)-3-[l-(ethyldimethylsilyl)cyclobutanecarboxamido]-N-(2-hydroxy-l-phenylethyl)-6,6-dimethyI-4,6-dihydropyiToIo[3,4-c]pyrazole-5(lH)-car boxamide, (S)-3-[2-(ethyldimethylsilyl)-2-methy]propaneamido]-N-(2-hydroxy-l-phenylethyl)-6,6-dimethyl-4,6-dihydropyiTolo[3,4-c]pyrazole-5(lH)-car boxamide, (S)-N-(2-hydroxy-l-phenylethyl)-N,6,6-trimethyl-3-[l-(trimethylsilyl)c yclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carb oxamide, (S)-2-[(2-methoxypropan-2-yl)oxy]-l-phenylethyl 6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydro pyrrolo[3,4-c]pyrazole-5(lH)-carboxylate, (S)-2-hydroxy-1 -phenylethyl 6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydro pyrrolo[3,4-c]pyrazole-5(lH)-carboxylate, 2-Methoxy-1 -phenylethyl 6,6-dimethyl-3-[l-(trimethylsily])cyclopropanecarboxamido]-4,6-dihydr opyrrolo[3,4-c]pyrazole-5( 1 H)-carboxylate, N-[5-(4-hydroxy-3-phenylbutanoyl)-6,6-dimethyl-l,4,5,6-tetrahydropyr rolo[3,4-c]pyrazol-3-yl]-l-(trimethylsilyl)cyclobutanecarboxamide, N-[5-(3-hydroxy-3-phenylpropanoyl)-6,6-dimethyl-l,4>5,6-tetrahydropy rrolo[3,4-c]pyrazol-3-yl]-l-(tiimethylsilyl)eyclobutanecarboxamide, (R)-N-(3-hydroxy-l-phenylpropyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cy clobutanecarboxamido]-4,6-dihydropyrrolo[3)4-c]pyrazole-5(lH)-carbo xamide,

(R)-N-(3-hydroxy-l-pheny]propyl)-6,6-dimethy]-3-[l-(trimethylsilyl)cy clopropanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-cai"b oxamide, (R)-N-(4-hydroxy-l-phenylbutyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cycl obutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carbox amide, (R)-N-(5-hydroxy-l-phenylpentyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cy clobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carbo xamide, (S)-N-(2-hydroxy-2-methy]-l-phenylpropyl)-6,6-dimethyl-3-[l-(trimeth y]silyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(l H)-carboxamide, (S)-N-(2-hydroxy-2-methyl-l-phenylpropyl)-6,6-diniethyl-3-[l-(trimeth ylsilyl)cyclopropanecarboxamido]-4,6-dihydropyiTolo[3,4-c]pyrazole-5( lH)-carboxamide, N-(3-hydroxy-2,2-dimethyl-l-phenylpropyl)-6,6-dimethyl-3-[l-(trimeth ylsilyl)cyclobutanecarboxamido]-4,6-dihydropyn-olo[3,4-c]pyrazole-5(l H)-carboxamide, (R)-N-(3-hydroxy-3-methyl-l-phenylbutyl)-6,6-dimethyl-3-[l-(trimethy lsilyl)cyclobutanecarboxamido]-4,6-dihydropyn-olo[3,4-c]pyrazole-5(l H)-carboxamide, (S)-N-(2-methoxy-l-phenylethyl)-6,6-dimethyl-3-[l-(trimethylsi]yl)cycl obutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carbox amide, (S)-N-[2-(difluoromethoxy)-l-phenylethyI]-6,6-dimethyl-3-[l-(trimethy lsi]yl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazo]e-5(l

H)-carboxamide, (S)-N-(2-ethoxy-1 -phenylethyl)-6,6-dimethyl-3-[ 1 -(trimethylsilyl)cyclo butanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxa mide, (R)-N-(3-methoxy-1 -phenylpropyl)~6,6-dimethy l-3-[ 1 -(trimethylsilyl)cy clobutanecarboxamido]-4,6-dihydropyiTolo[3,4-c]pyrazole-5(lH)-carbo xamide, Sodium (S)-2-{6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutanecarboxamido]-l,4. 5.6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamide}-2-phenylacetate, (R)-N-(2-hydroxy-1 -phenylethyl)-6,6-dimethyl-3-[ 1 -(trimethylsilyl)cycl obutanecarboxamido]-4,6-dihydropyiTolo[3,4-c]pyrazole-5(lH)-carbox amide, N-[l-(2-fluorophenyl)-2-hydroxyetliyl]-6,6-dimethyl-3-[l-(trimethylsily l)cyclobutanecarboxamido]-4,6-dihydropyiTolo[3,4-c]pyrazole-5(lH)-c arboxamide, (S)-N-[ 1 -(3-fluorophenyl)-2-hydroxyethyl]-6,6-dimethyl-3-[ 1 -(trimethy lsilyl)cyclobutanecarboxamido]-4,6-dihydropyn-olo[3,4-c]pyrazole-5(l H)-carboxamide, (S)-N-[ 1 -(4-fluorophenyl)-2-hydroxyethyl]-6,6-dimethyl-3-[ 1 -(trimethy lsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(l H)-carboxamide, N-[2-hydroxy-l-(pyridin-2-yl)ethyl]-6,6-dimethyl-3-[l-(trimethylsilyl)c yclobutanecarboxamido]-4,6-dihydropyn-olo[3,4-c]pyrazole-5(lH)-carb oxamide, N-[2-hydroxy-l-(pyridin-3-yl)ethyl]-6,6-dimethyl-3-[l-(trimethylsilyl)c

yclobutanecarboxamido]-4,6-dihydropyiTolo[3,4-c]pyrazole-5(lH)-carb oxamide, N-[l-(benzo[d][l,3]dioxol-4-yl)-2-hydroxyethyl]-6,6-dimethyl-3-[l-(tri methylsilyl)cyclobutanecarboxamido]-4,6-dibydropyiTolo[3,4-c]pyrazol e-5(lH)-carboxamide, (S)-N-(l-cyclohexyl~2-hydroxyethyl)-6,6-dimetbyl-3-[l-(trimethylsilyl) cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-car boxamide, (S)-N-( 1 -hydroxy-3-methylbutan-2-yl)-6,6-dimethyl-3-[ 1 -(trimethylsily l)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyi-azole-5(lH)-c arboxamide, (S)-N-(l-hydroxypropan-2-yl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclob utanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazoIe-5(lH)-carboxam ide, N-(2-hydroxyethyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutanecarbo xamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide, N-(2-hydroxy-2-phenylethyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobu tanecarboxamido]-4,6-dihydropyiTolo[3,4-c]pyrazole-5(lH)-carboxami de, N-(2-hydroxypropyl)-6,6-dimethyl-3-[]-(trimethylsilyl)cyclobutanecarb oxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxaraide, N-[(2S)-1 -hydroxy-3-methyl-1 -phenylbutan-2-yl]-6,6-dimethyl-3-[ 1 -(tri methylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazol e-5(lH)-carboxamide, N-(4-hydroxy-1 -phenyl-2-butyn-1 -yl)-6,6-dimethyl-3-[ 1 -(trimethylsilyl) cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(rH)-car

boxamide, (S)-2-{6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutanecarboxamido]-l,4, 5,6-tetrahydropyrro]o[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl acetate, (S)-2-{6,6-diraethyl-3-[l-(trimethylsilyl)cyclobutanecarboxaniido]-l,4, 5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl propionate, (S)-2-{6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutanecarboxamido]-l,4. 5,6-tetrahydropyiTolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl butanoate, (S)-2-{6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutanecarboxamido]-l,4, 5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl pentanoate, (S)-2-{6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutanecarboxaraido]-l,4, 5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl octanoate, (S)-2-{6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutanecarboxamido]-l,4. 5,6-tetrahydropyrro]o[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl dodecanoate, (S)-2-{6,6-dimethyl-3-[l-(trimethylsilyl)cyc]obutanecarboxamido]-l,4; 5,6-tetrahydropyn-olo[3,4-c]pyrazoJe-5-carboxamido}-2-phenylethyl palmitate, (S)-2-{6,6-diraethyl-3-[l-(trimetbylsilyl)cyclobutanecarboxamido]-l,4, 5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyJ isobutanoatc, (S)-2-{6,6-dimethyl-3-[l-(trimethylsi]yl)cyclobutanecarboxamido]-l,4,

5,6-tetrahydi-opyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethy] pivalate, (S)-2- (6,6-dimethyl-3-[ 1 -(trimethylsilyl)cyclobutanecarboxamido]-l ,4, 5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl 3-methylbutanoate, (S)-2-{6,6-dimethyl-3-[l-(tnmethylsilyl)cyclobutanecarboxamido]-l,4, 5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl benzoate, (S)-2-{6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutanecarboxamido]-l,4, 5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl ethyl carbonate, Sodium (S)-4-(2-{6,6-dimethyl-3-[l-(ti-imethylsilyl)cyclobutanecarboxamido]-l, 4,5,6-tetrahydi-opyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethoxy )-4-oxobutanoate, (S)-(2-{6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutanecarboxamido]-l,4, 5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethoxy) methyl pivalate, (S)-2-acetoxy-1 -phenylethyl 6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydro pyrrolo[3,4-c]pyrazole-5(lH)-carboxylate, (S)-benzyl 2- {6,6-dimethyl-3-[ 1 -(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-t etrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylacetate, (S)-methyl 2-{6,6-dimethyl-3-[l-(trimethylsilyl)cyelobutanecarboxamido]-l,4,5,6-t

etrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenyiacetate, N-(2,2-difluoi"0-3-hydroxy-l-phenylpropyl)-6,6-dimethyl-3-[l-(trimeth ylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(l H)-carboxamide, N-(2-isopropoxy-1 -phenylethyl)-6,6-dimethyl-3-[ 1 -(trimethylsilyl)cyclo butanecarboxamido]-4,6-dihydropyn-olo[3,4-c]pyrazole-5(lH)-carboxa mide, 6,6-Dimethyl-N-(2-phenoxy-1 -phenylethyl)-3-[ 1 -(trimethylsilyl)cyclob utanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxam ide, (S)-N-[l-(2-chlorophenyl)-2-hydroxyethyl]-6,6-dimethy]-3-[l-(trimethy lsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyi-azole-5(] H)-carboxamide, (S)-N-[2-hydroxy-l-(o-tolyl)ethyl]-6,6-dimethyl-3-[l-(trimethyIsilyl)cy clobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carbo xamide, (S)-N-( 1 -hydroxy-3-phenylpropan-2-yl)-6,6-dimethyl-3-[ 1 -(trimethylsil yl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide, N-(2-hydroxy-3-methylbutyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobu tanecarboxamido]-4,6-dihydropyiTolo[3,4~c]pyrazole-5(lH)-carboxami de, (R)-N-( 1 -hydroxy-3-phenylpropan-2-yl)-6,6-dimethyl-3-[ 1 -(trimethylsil yl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide, (R)-N-(2-hydroxy-2-phenylethyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cycl

obutanecarboxamido]-4,6-dihydropyiTolo[3,4-c]pyrazole-5(lH)-carbox amide, (S)-N-(2-hydroxy-2-phenylethyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cycl obutanecai-boxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carbox amide, 2-Hydroxy-2-phenylethyl 6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydro pyrrolo[3,4-c]pyrazole-5(lH)-carboxylate, (R)-N-[6,6-dimethyl-5-(2-phenoxypropanoyl)-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-yl]-l-(trimethylsilyl)cyclobutanecarboxamide, (S)-N-[6,6-dimethyl-5-(2-phenoxypropanoyl)-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-yl]-l-(trimethylsilyl)cyclobutanecarboxamide, N-[6,6-dimethyl-5-(2-phenoxyacetyl)-l,4,5,6-tetrahydropyrrolo[3,4-c]p yrazol-3-yl]-l-(trimethylsilyl)cyclobutanecarboxamide, (R)-N-[6,6-dimethyl-5-(2-phenoxypropanoyl)-l,4,5,6-tetrahydropyiTolo [3,4-c]pyrazol-3-yl]-l-(trimethylsilyl)cyclopropanecarboxamide, N-{5-[3-(benzyloxy)-2-phenoxypropanoyl]-6,6-dimethyl-l,4,5,6-tetrahy dropyrrolo[3,4-c]pyrazol-3-yl}-l-(trimethylsilyl)cyclobutanecarboxami de, N-[5-(3-hydroxy-2-phenoxypropanoyl)-6,6-dimethyl-l,4,5,6-tetrahydro pyrrolo[3,4-c]pyrazol-3-y]]-l-(trimethylsilyl)cyclobutanecarboxamide, N-{5-[2-(4-chlorophenoxy)propanoyl]-6,6-dimethyl-l,4,5,6-tetrahydrop yrrolo[3,4-c]pyrazol-3-yl}-l-(trimethy.lsilyl)cyclobutanecarboxamide, N-{5-[2-(2-chlorophenoxy)propanoyl]-6,6-dimethyl-l,4,5,6-tetrahydrop yiTolo[3,4-c]pyrazol-3-yl}-l-(trimethylsilyl)cyclobutanecarboxamide, N-{5-[2-(cyclohexyloxy)propanoyl]-6,6-dimethyl-l,4,5,6-tetrahydropyr

rolo[3,4-c]pyrazol-3-yl}-l-(trimethylsilyl)cyclobutanecarboxamide, N-{5-[2-(3-chlorophenoxy)propanoyl]-6,6-dimethyl-l,4,5,6-tetrahydrop yrrolo[3,4-c]pyrazol-3-yl}-l-(trimethylsilyl)cyclobutanecarboxamide, N-[5-(2-methoxypropanoyl)-6,6-dimethyl-l,4,5,6-tetraliydropyrrolo[3,4 -c]pyrazol-3-yl]-l-(trimethylsilyl)cyclobutanecarboxamide, N-[5-(3-methoxy-2-phenoxypropanoyl)-6,6-dimethyl-l,4,5,6-tetrahydro pyrroIo[3,4-c]pyrazol-3-yl]-l-(trimethylsilyl)cyclobutanecarboxamide, N-{6,6-dimethyl-5-[2-(pyridin-3-yloxy)propanoyl]-l,4,5,6-tetrahydropy rrolo[3,4-c]pyrazol-3-yl}-l-(trimethylsilyl)cyclobutanecarboxamide, N-{5-[3-(dimethylamino)-2-phenoxypropanoyl]-6,6-dimethyl-l,4,5,6-te trahydropyrrolo[3,4-c]pyrazol-3-yl}-l-(trimethylsilyl)cyclobutanecarbo xamide, N-[6,6-dimethyl-5-(2-phenoxy-2-phenylacetyl)-l,4,5,6-tetrahydropyrro] o[3,4-c]pyrazol-3-yl]-l-(trimethylsilyl)cyclobutanecarboxamide, N-{5-[3-(3,3~difluoropyrrolidin-l-yl)-2-phenoxypropanoyl]-6,6-dimeth yl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-l-(trimethylsilyl)cyclo butanecarboxamide, N-[5-(3-hydroxy-2-phenylpropanoyl)-6,6-dimethyl-l,4,5,6-tetrahydropy rrolo[3,4-c]pyrazol-3-yl]-l-(trimethylsilyl)cyclobutanecarboxamide, (S)-N-[5-(3-hydroxy-2-pheny]propanoyl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-yl]-l-(trimethylsilyl)cyclobutanecarboxamide (R)-N-{5-[3-(benzyloxy)-2-phenylpropanoyl]-6,6-dimethyl-l,4,5,6-tetra hydropyrrolo[3,4-c]pyrazol-3-yl}-l-(trimethylsilyl)cyclobutanecarboxa midc, (R)-N-[5-(3-hydroxy-2-phenylpropanoyl)-6,6-dimethyl-l,4,5,6-tetrahyd

ropyiTolo[3?4-c]pyrazol-3-yl]-l-(trimethylsilyl)cyclobutanecarboxamide (R)-N-[5-(2-methoxy-2-phenylacetyl)-6,6-dimethyl-l,4,5,6-tetrahydrop yiTolo[3,4-c]pyrazol-3-yl]-l-(trimethylsilyl)cyclobutanecarboxamide. (S)-N-[5-(2-methoxy-2-phenylacetyl)-6,6-dimethyl-l,4,5,6-tetrahydrop yrrolo[3?4-c]pyrazol-3-yl]-l-(trimethylsilyl)cyclobutanecarboxamide, N-[5-(3-methoxy-2-phenylpropanoyl)-6,6-dimethyl-l,4,5,6-tetrahydrop yn-olo[3,4-c]pyrazol-3-yl]-l-(trimethylsily])cyclobutanecarboxamide, N-[5-(4-methoxy-2-phenylbutanoyl)-6,6-dimethyl-l,4,5,6-teti-ahydi-opyr rolo[3,4-c]pyrazol-3-yl]-l-(trimethylsilyl)cyclobutanecarboxamide, (S)-N-[5-(3-hydroxy-2-phenylpropanoyl)-6,6-diraethyl-l,4,5,6-tetrahyd ropyn-olo[3,4-c]pyrazol-3-yl]-l-(trimethylsilyl)cyclopropanecarboxami de, (R)-N-[5-(2-methoxy-2-phenylacetyl)-6,6-dimethyl-l,4,5,6-tetrahydrop yrrolo[3,4-c]pyrazol-3-yl]-l-(trimethylsilyl)cyclopropanecarboxaraide, (R)-N-{5-[2-(difluoromethoxy)-2-phenylacetyl]-6,6-dimethyl-l,4,5,6-te trahydropyiTolo[3,4-c]pyrazol-3-yl}-l-(trimethylsilyl)cyclobutanecarbo xamide, (R)-N-[5-(2-ethoxy-2-phenylacetyl)-6,6-dimethyl-l,4,5,6-tetrahydropyrr olo[3,4-c]pyrazol-3-yl]-l-(trimethylsilyl)cyclobutanecarboxamide, (R)-l-(ethyldimethylsilyl)-N-[5-(2-methoxy-2-phenylacetyl)-6,6-dimeth ybl,4,5,6-tetrahydropyn"olo[3,4-c]pyrazol-3-yl]cyclobutanecarboxaraid e, (R)-N-[5-(2-cyclopropoxy-2-phenylacetyl)-6:,6-dimediyl-l?4:,5,6-tetrahy dropyrrolo[3,4-c]pyrazol-3-y]]~l-(trimethylsilyl)cyclobutanecarboxamid

(R)-N-[5-(2-isopropoxy-2-phenylacety l)-6,6-dimethyl-1,4,5,6-tetrahydr opyrrolo[3,4-c]pyrazol-3-yl]-l-(trimethylsilyl)cyclobutanecarboxamide, (R)-N-{6,6-dimethyl-5-[2-phenyl-2~(trifluoromethoxy)acetyl]-l,4,5,6-te trahydi-opyn-olo[3,4-c]pyrazol-3-yl}-l-(trimethylsilyl)cyclobutanecarbo x amide, (R)-N-[6,6-dimethyl-5-(2-phenyl-2-propoxyacetyl)-l,4,5,6-tetrahydropy rrolo[3,4-c]pyrazol-3-yl]-l-(trimethylsilyl)cyclobutanecarboxamide, N-{5-[2-(4-fluorophenyl)-2-methoxyacetyl]-6,6-dimethyl-l,4,5,6-tetrah ydi'opyrrolo[3,4-c]pyrazol-3-yl}-l-(trimethylsilyl)cyclobutanecarboxam ide, N- {5-[2-(3-fluorophenyl)-2-metIioxyacetyl]-6,6-dimethyI-1,4,5,6-tetrah ydropyn-olo[3,4-c]pyrazol-3-yl}-l-(trimethylsilyl)cyclobutanecarboxam ide, (R)-N-{5-[2-(2-fluorophenyl)-2-methoxyacetyl]-6,6-dimethyl-l,4,5,6-te trahydropyrrolo[3,4-c]pyrazol-3-yl}-l-(trimethylsilyl)cyclobutanecarbo xamide, N-{5-[2-methoxy-2-(thiophen-2-yl)acetyl]-6,6-dimethyl-l,4,5,6-tetrahy dropyrrolo[3,4-c]pyrazol-3-yl}-l-(trimethylsilyl)cyclobutanecarboxami de, (-)-N- {5-[2-methoxy-2-(thiophen-2-yl)acetyl]-6,6-dimethyl-1,4,5,6-tetra hydropyrrolo[3,4-c]pyrazol-3~yl}-l-(trimethylsilyl)cyclobutanecarboxa mide, (+)-N-{5-[2-methoxy-2-(thiopben-2-yl)acetyl]-6,6-dimethyl-l,4,5,6-tetr ahydropyrrolo[3,4-c]pyrazo]-3-yl}-l-(trimethylsilyl)cyciobutanecarbox amide, N-{[l-(hydi-oxymethyl)cyclobutyl](phenyl)methyl}-6,6-dimethyl-3-[l-(

trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyraz ole-5(lH)-carboxamide, (R)-N-[2-( 1 -hydro xycyclopropyl)-1 -phenylethyl]-6,6-dimethyl-3-[ 1 -(tri methylsilyl)cyclobutanecarboxamido]-4,6-dihydropyiTolo[3,4-c]pyrazol e-5(lH)-carboxamide, (R)-N-(3-ethyl-3-hydroxy-1 -phenylpentyl)-6,6-dimethyl-3-[ 1 -(trimethyl silyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH )-carboxamide, (R)-N-[l-(4-fluorophenyl)-3-hydroxy-3-methylbutyl]-6,6-dimethyl-3-[l -(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyiTolo[3,4-c]pyr azole-5 (1 H)-carboxamide, (R)-N-[ 1 -(3-fluorophenyl)-3-hydroxy-3-methylbutyl]-6,6-dimethyl-3-[ 1 -(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyiTolo[3,4-c]pyr azole-5(lH)-carboxamide, (R)-N-[l-(2-fluorophenyI)-3-hydroxy-3-methylbutyI]-6,6-dimethyl-3-[l -(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyr azole-5(lH)-carboxamide, (R)-N-(5-hydroxy-2,5-dimethylhexan-3-yl)-6,6-dimethyl~3-[l-(trimethy lsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(l H)-carboxaraide, N-[l-(4-fluorophenyl)-3-hydroxy2,2-diraethylpropyl]-6,6-dimethyl-3-[l -(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyr azole-5(lH)-carboxamide, N-[l-(3-fluorophenyl)-3-hydroxy-2,2-dimethylpropyl]-6,6-dimethyl-3-[ l-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]py razole-5( 1 H)-carboxamide,

(-)-N-[l-(3-fluorophenyl)-3-hydroxy-2,2-dimethylpropyl]-6,6-dimethyl- 3-[l-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyn-olo[3,4-c ]pyrazole-5( 1 H)-carboxamide, (+)-N-[l-(3-fluorophenyl)-3-hydroxy-2,2-dimethylpropyl]-6,6-dimethyl -3-[l-(tiimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrroIo[3,4-c]pyrazole-5(lH)-carboxamide, N-[l-(2-fluorophenyl)-3-hydroxy-2,2-dimethylpropyl]-6,6-dimethyl-3-[ l-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]py razole-5(lH)-carboxamide, N-( 1 -hydroxy-2,2,4-trimethylpentan-3-yl)-6,6-dimethyl-3-[l -(trimethyls ilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH) -carboxamide, (R)-N-(3-hydroxy-3-methyl-l-phenylbutyl)-6,6-dimethyl-3-[l-(trimethy lsilyl)cyclopropanecarboxamido]-4;,6-dihydropyiTolo[3,4-c]pyrazole-5(] H)-carboxamide, N-(3-hydi-oxy-2,2-dimethyl-l-pheny]propyl)-6,6-dimethyl-3-[l-(trimeth ylsilyl)cycJopropanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5( lH)-carboxamide, (-)-N-(3-hydroxy-2,2-dimethyl-1 -phenylpropyl)-6,6-dimetiiyl-3-[ 1 -(trim ethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole- 5(1 H)-carboxamide, (+)-N-(3-hydroxy-2,2-dimethyl-l-pber)ylpropyl)-6,6-dimethyl-3-[l-(tri methylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazol e-5(.l H)-carboxamide, (R)-N-[5-(2-butoxy-2-phenylacetyl)-6,6-dimethyl-l,4,5,6-tetrahydropyr rolo[3,4-c]pyrazol-3-yl]-1 -(trimethylsiJyJ)cyclobutanecarboxamide, and

N-(3-methoxy-2,2-dimethyl-1 -phenylpropyl)-6,6-dimethyl-3-[ 1 -(trimet hylsilyl)cyclobutanecai"boxamido]-4,6-dihydropyn-olo[3,4-c]pyrazole-5( 1 H)-carboxamide or a pharmacologically acceptable salt thereof. 12. (R)-N-[l-(4-fluorophenyl)-3-hydroxy-3-methylbutyl]-6,6-dimet hyl-3-[l-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3 ,4-c]pyrazole-5(lH)-carboxamide or a pharmacologically acceptable salt thereof. 13. (-)-N-(3-hydroxy-2,2-dimethyl-1-phenylpropyl)-6,6-dimethyl-3-[l-(trimethylsilyl)cyclopropane-l-carboxamido]-4,6-dihydropyrrolo[3,4 -c]pyrazole-5(lH)-carboxamide or a pharmacologically acceptable salt thereof 14. (R)-N-[5-(2-methoxy-2-phenylacetyl)-6,6-dimethyl-l,4,5,6-tetra hydropyiTolo[3,4-c]pyrazol-3-yl]-l-(trimethylsilyl)cyclobutanecarboxa mide or a pharmacologically acceptable salt thereof. 15. (R)-N-[6,6-dimethyl-5-(2-phenyl-2-propoxyacetyl)-l,4,5,6-tetra hydropyn-olo[3,4-c]pyrazol-3-yl]-l-(trimethylsilyl)cyclobutanecarboxa mide or a pharmacologically acceptable salt thereof. 16. (R)-N- {5-[2-(2-fluorophenyl)-2-methoxyacetyl]-6,6-dimethyl-1, 4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-l-(trimethylsilyl)cyclobuta necarboxamide or a pharmacologically acceptable salt thereof

17. (R)-N-[5-(2-ethoxy-2-phenylacetyl)-6,6-dimethyl-l,4,5,6-teti-ah ydropyrrolo[3,4-c]pyrazol-3-y]]-l-(trimethylsilyl)cyclobutanecarboxami de or a pharmacologically acceptable salt thereof. 18. (R)-N-[5-(2-cyclopropoxy-2-phenylacetyl)-6,6-dimethyl-1,4,5,6 -tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-l-(trimethylsilyl)cyclobutanecar boxamide or a pharmacologically acceptable salt thereof. 19. (R)-N-[5-(2-isopropoxy-2-phenylacetyl)-6,6-dimethyl-l,4,5,6-te trahydropyrrolo[3,4-c]pyrazol-3-yl]-l-(trimethylsilyl)cyclobutanecarbo xamide or a pharmacologically acceptable salt thereof. 20. (+)-N-{5-[2-methoxy-2-(thiophen-2-yl)acetyl]-6,6-dimethyl-l,4, 5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-l-(trimethylsilyl)cyclobutane carboxamide or a pharmacologically acceptable salt thereof. 21. (-)-N-[l-(3-fluorophenyl)-3-hydroxy-2,2-dimethylpropyl]-6,6-di methyl-3-[l-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrol o[3,4-c]pyrazole-5(lH)-carboxamide or a pharmacologically acceptable salt thereof. 22. N-{5-[2-(3-fluorophenyl)-2-methoxyacetyl]-6,6-dimethyl-l ,4,5, 6-tetrahydropyiTolo[3,4-c]pyrazol-3-yl}-l-(trimethylsilyl)cyclobutaneca rboxamide or a pharmacologically acceptable salt thereof. 23.

N-[l-(4-fluorophenyl)-3-hydroxy-2f2-dimethylpropyl]-6,6-dime thyl-3-[l-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[ 3,4-c]pyrazole-5(lH)-carboxamide or a pharmacologically acceptable salt thereof. 24. (R)-N-[ 1 -(3-fluorophenyl)-3-hydroxy-3-methylbutyl]-6,6-dimet hyl-3-[l-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3 ,4-c]pyrazole-5(lH)-carboxamide or a pharmacologically acceptable salt thereof. 25. (R)-N- {6,6-dimethyl-5-[2-phenyl-2-(trifluoromethoxy)acetyl]-1, 4,5,6-tetrahy dropyrrolo [3,4-c]pyrazol-3-yl} -1 -(trimethylsilyl)cyclobuta necarboxamide or a pharmacologically acceptable salt thereof 26. (R)-N-[2-(l-hydroxycyclopropyl)-l-phenylethyl]-6,6-dimethyl-3-[l-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyn-olo[3,4-c ]pyrazole-5(lH)-carboxamide or a pharmacologically acceptable salt thereof. 27. (R)-N-(3-hydroxy-3-methyl-l-phenylbutyl)-6,6-dimethyl-3-[l-(t rimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyraz ole-5(lH)-carboxamide or a pharmacologically acceptable salt thereof. 28. (R)-N-[5-(2-methoxy-2-phenylacetyl)-6,6-dimethyl-l,4,5,6-tetra hydropyiTolo[3,4-c]pyrazol-3-yl]-l-(trimethylsilyl)cyclopropanecarboxa mide or a pharmacologically acceptable salt thereof.

29. (R)-N- {5-[2-(difluoromethoxy)-2-pheny]acetyl]-6,6-dimethyl-1, 4,5,6-tetrahydropyn-olo[3,4-c]pyrazol-3-yl}-l-(trimethylsilyl)cyclobuta necarboxamide or a phannacologically acceptable salt thereof. 30. (R)-l-(ethyldimethylsilyl)-N-[5-(2-methoxy-2-phenylacetyl)-6,6 -dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]cyclobutanecarb oxamide or a phannacologically acceptable salt thereof. 31. N- {[ 1 -(hydroxymethyl)cyclobutyl](phenyl)methyl} -6,6-dimethy l-3-[l-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide or a phannacologically acceptable salt thereof. 32. A pharmaceutical composition comprising the compound or a phannacologically acceptable salt thereof according to any one of claims 1 to 31. 33. The pharmaceutical composition according to claim 32, wherein the phannaceutical composition is a CDK7 inhibitor. 34. The pharmaceutical composition according to claim 32 or 33, wherein the pharmaceutical composition is for treating or preventing a cancer or an inflammatory disease. 35. The phannaceutical composition according to claim 34, wherein the inflammatory disease is an autoimmune disease. 36. The phannaceutical composition according to claim 35, wherein the autoimmune disease is rheumatoid arthritis. 37. The phannaceutical composition according to claim 35, wherein

the autoimmune disease is psoriasis.